01 6Orenitram
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 225
2018 Revenue in Millions : 205
Growth (%) : 10
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 293
2019 Revenue in Millions : 225
Growth (%) : 30
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 306
2020 Revenue in Millions : 293
Growth (%) : 4
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 325
2021 Revenue in Millions : 306
Growth (%) : 6
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 359
2022 Revenue in Millions : 325
Growth (%) : 11
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 434
2023 Revenue in Millions : 359
Growth (%) : 21
